CD4 and peripheral arterial disease: These data reveal that inactivated vaccine‐elicited CD4+ T cell responses are long‐lasting and could be boosted to a greater magnitude by a third dose in PAD (Figure S14), suggesting that PAD may benefit more from the boost dose.